5/3
11:32 pm
alks
Alkermes plc (NASDAQ: ALKS) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
Low
Report
Alkermes plc (NASDAQ: ALKS) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
5/2
02:07 pm
alks
Alkermes plc (NASDAQ: ALKS) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock.
Low
Report
Alkermes plc (NASDAQ: ALKS) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock.
5/2
01:42 pm
alks
Alkermes' (ALKS) Q1 Earnings & Revenues Fall Shy of Estimates [Yahoo! Finance]
Low
Report
Alkermes' (ALKS) Q1 Earnings & Revenues Fall Shy of Estimates [Yahoo! Finance]
5/2
07:00 am
alks
Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk
Low
Report
Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk
5/2
07:00 am
alks
Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk
Low
Report
Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk
5/1
11:25 am
alks
Alkermes (ALKS) Reports Q1 Earnings: What Key Metrics Have to Say [Yahoo! Finance]
Low
Report
Alkermes (ALKS) Reports Q1 Earnings: What Key Metrics Have to Say [Yahoo! Finance]
5/1
07:12 am
alks
Alkermes plc Reports First Quarter 2024 Financial Results [Yahoo! Finance]
Low
Report
Alkermes plc Reports First Quarter 2024 Financial Results [Yahoo! Finance]
5/1
07:00 am
alks
Alkermes plc Reports First Quarter 2024 Financial Results
Low
Report
Alkermes plc Reports First Quarter 2024 Financial Results
5/1
07:00 am
alks
Alkermes plc Reports First Quarter 2024 Financial Results
Low
Report
Alkermes plc Reports First Quarter 2024 Financial Results
4/24
07:10 am
alks
Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1 [Yahoo! Finance]
Low
Report
Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1 [Yahoo! Finance]
4/24
07:00 am
alks
Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1
Low
Report
Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1
4/24
07:00 am
alks
Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1
Low
Report
Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1
4/22
03:58 pm
alks
Will Alkermes' (ALKS) Proprietary Drugs Aid Amid Competition? [Yahoo! Finance]
Neutral
Report
Will Alkermes' (ALKS) Proprietary Drugs Aid Amid Competition? [Yahoo! Finance]
4/19
08:03 am
alks
Alkermes plc (NASDAQ: ALKS) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock.
Low
Report
Alkermes plc (NASDAQ: ALKS) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock.
4/17
04:00 pm
alks
Alkermes to Report First Quarter Financial Results on May 1, 2024
Low
Report
Alkermes to Report First Quarter Financial Results on May 1, 2024
4/17
04:00 pm
alks
Alkermes to Report First Quarter Financial Results on May 1, 2024
Low
Report
Alkermes to Report First Quarter Financial Results on May 1, 2024
4/16
11:29 am
alks
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick [Yahoo! Finance]
Low
Report
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick [Yahoo! Finance]
4/11
11:41 am
alks
Alkermes' (ALKS) ALKS 2680 Betters Wakefulness in Phase Ib Study [Yahoo! Finance]
Low
Report
Alkermes' (ALKS) ALKS 2680 Betters Wakefulness in Phase Ib Study [Yahoo! Finance]
4/9
12:09 pm
alks
Alkermes plc (NASDAQ: ALKS) had its price target raised by analysts at Jefferies Financial Group Inc. from $42.00 to $50.00. They now have a "buy" rating on the stock.
Low
Report
Alkermes plc (NASDAQ: ALKS) had its price target raised by analysts at Jefferies Financial Group Inc. from $42.00 to $50.00. They now have a "buy" rating on the stock.
4/9
09:53 am
alks
Alkermes Plc: Collecting The Fruits Of The 2023 Spinoff [Seeking Alpha]
Low
Report
Alkermes Plc: Collecting The Fruits Of The 2023 Spinoff [Seeking Alpha]
4/9
07:15 am
alks
Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia [Yahoo! Finance]
Low
Report
Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia [Yahoo! Finance]
4/9
07:00 am
alks
Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia
Medium
Report
Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia
4/9
07:00 am
alks
Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia
Medium
Report
Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia
4/8
07:18 am
alks
Alkermes Presents Analyses From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan) at 2024 Congress of the Schizophrenia International Research Society [Yahoo! Finance]
Low
Report
Alkermes Presents Analyses From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan) at 2024 Congress of the Schizophrenia International Research Society [Yahoo! Finance]
4/8
07:00 am
alks
Alkermes Presents Analyses From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan) at 2024 Congress of the Schizophrenia International Research Society
Low
Report
Alkermes Presents Analyses From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan) at 2024 Congress of the Schizophrenia International Research Society